Neoleukin Therapeutics Inc(NLTX)stock report

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Finance:
Market Cap:592.2M; Shares Outstanding:48.6M; Q3 2019(9/30/19): Cash 66.31M. Loss 59.13M

EPS and Sales:
https://finance.yahoo.com/quote/NLTX/financials?p=NLTX

Date EPS % last year % last quarter
2018.12.31 -1.3419 37.24% -17.71%
2019.3.31 -0.09 85.48% 93.29%
2019.6.30 -0.09 82.00% 0.00%
2019.9.30 -2.51 -120.18% -2688.89%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=NLTX&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/NLTX/institutional-ownership/

2019.12.29:
Total institutions: 43,no change
Shares hold: 18840.1k shares. no change
shares% hold: 39.84%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/NLTX/price-targe

Leave a Reply